Hims & Hers Plunges 12% After Fourth Q1 Miss, Notes 125,000 Wegovy Shipments
Hims & Hers fell over 12% after missing Q1 FY2026 revenue and earnings consensus for the fourth time in five quarters. The company fulfilled more than 125,000 Wegovy shipments via its GLP-1 partnership with Novo Nordisk and lifted full-year guidance on strong telehealth and weight-loss demand.
1. Q1 Earnings and Stock Reaction
Hims & Hers missed consensus on both revenue and earnings in Q1 FY2026 for the fourth time in five quarters, resulting in a 12% drop in its share price. The persistent shortfall underscores challenges in scaling telehealth services profitably.
2. GLP-1 Partnership Drives Shipments
The Novo Nordisk collaboration delivered over 125,000 Wegovy shipments during Q1, marking significant uptake of the company's GLP-1 offering. This segment is emerging as a core growth pillar within its weight-loss portfolio.
3. Raised Guidance and Market Position
On the strength of GLP-1 traction, Hims & Hers increased its full-year revenue and earnings guidance. The company remains focused on high-growth markets—telehealth, weight management and hair thinning—with analysts retaining constructive long-term views despite near-term volatility.